Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in pulmonary arterial hypertension related to congenital heart disease
2016-003495-53Phase 3Active
- Sponsor
- Academic Medical Center
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of selexipag in congenital heart disease-associated pulmonary hypertension (CHD-PAH), sponsored by Academic Medical Center. Primary endpoint: percentage change in exercise capacity. Started Dec 2016; status: active.
02
Drugs
selexipag
03
Conditions
congenital heart disease-associated pulmonary hypertension (CHD-PAH)
Beyond the preview
Go deeper on 2016-003495-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003495-53.